A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors

November 21, 2025 updated by: Paolo Bonato, Spaulding Rehabilitation Hospital

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Subacute Stroke Survivors

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Study Overview

Detailed Description

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Study participants will be asked to take part in 4 evaluation study visits: one screening and enrollment visit, and three evaluation visits (at baseline, at 3 months and at 6 months - at the intervention completion). Subject upper-extremity motor function will be assessed across domains of the International Classification of Functioning, Disability and Health (ICF) model. Groups will be stratified by baseline motor impairment and stroke chronicity.

Subjects randomized to the intervention group will take part of weekly coaching sessions during the first month, bi-weekly sessions during the months 2 and 3, and monthly sessions during months 4-6. These sessions will be held in-person or remotely, based on the study participant preference.

Subjects randomized to the control group will take part of monthly visits, held in-person or remotely (based on study participant preference), to re-evaluate the home-exercise plan and prescribe an update list of exercises for the following month.

Study Type

Interventional

Enrollment (Estimated)

88

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02129
        • Recruiting
        • Spaulding Rehabilitation Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female, 18-85 years of age at the time of enrollment
  • Anterior circulation ischemic stroke at least 1 month and no more than 6 months prior to study enrollment;
  • Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;
  • Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3step command) ;
  • Owning a smartphone (iOS or Android) and being familiar and comfortable with and owning a tablet or smartphone
  • SAFE score equal or greater than 5

Exclusion Criteria:

  • Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;
  • Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see the feedback on the app screen (as assessed with the Mesulum cancellation test);
  • Individuals with open wounds or recent fracture (less than 3 months) in the upper extremity, fragile skin or active infection;
  • Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;
  • Diagnosis of other neurological disease; (i.e., Parkinson's disease, multiple sclerosis, ...);
  • Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening;
  • Not understanding spoken or written English;
  • Contralateral motor deficits as assessed by clinical examination;
  • Brainstem and cerebellar stroke.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: StrokeWear Motor and Behavioral Intervention
Stroke survivors randomized to this group will receive standard rehabilitation (i.e., physical and occupational therapy) as well as a behavioral intervention aimed to encourage the use of the stroke affected arm during the performance of activities of daily living.
Behavioral strategies will be incorporated into the Strokewear system to encourage feedback on behavior, goal setting, daily activity action planning (DAAP), and an empowerment/ self management model to foster planned hemiparetic UE use during daily activities in the home and community. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to self- manage their GDM and DAAP.
Other: Sham Comparator: Usual Care
Stroke survivors randomized to this group will receive standard rehabilitation (i.e., physical and occupational therapy).
The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Motor Activity Log-Amount of Use
Time Frame: Change from baseline Motor Activity Log-Amount of Use score at 6 months
Self-reported measure of upper-extremity performance. Score from 0 (worst) to 5 (best)
Change from baseline Motor Activity Log-Amount of Use score at 6 months
Change in Fugl-Meyer Upper-Extremity
Time Frame: Change from baseline Fugl-Meyer Upper-Extremity score at 6 months
Observed measure of upper-extremity motor impairment following a stroke. Score from 0 (worst) to 66 (best)
Change from baseline Fugl-Meyer Upper-Extremity score at 6 months
Change in Upper-Extremity Activity Counts
Time Frame: Change from baseline Upper-Extremity Activity Counts score at 6 months
Activity of the hemiparetic upper-extremity in the home setting as measured with wrist-worn accelerometers
Change from baseline Upper-Extremity Activity Counts score at 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Motor Activity Log-Quality of Use
Time Frame: Change from baseline Motor Activity Log-Quality of Use score at 6 months
Self-reported measure of upper-extremity quality of use. Score from 0 (worst) to 5 (best)
Change from baseline Motor Activity Log-Quality of Use score at 6 months
Change in Wolf-Motor Function Test - Time subscale
Time Frame: Change from baseline Wolf-Motor Function Test - Time subscale score at 6 months
Observed (timed) measure of upper-extremity function. Time from 0 to 120 seconds (maximum time allowed to attempt to perform a motor task)
Change from baseline Wolf-Motor Function Test - Time subscale score at 6 months
Change in Wolf-Motor Function Test - Functional ability subscale
Time Frame: Change from baseline Wolf-Motor Function Test - Functional ability subscale score at 6 months
Measure of upper-extremity quality of movement based on visual observation. Score from 0 (worst) to 5 (best)
Change from baseline Wolf-Motor Function Test - Functional ability subscale score at 6 months
Change in Stroke Impact Scale (SIS)
Time Frame: Change from baseline Stroke Impact Scale (SIS) score at 6 months
Self-reported measure of quality of life after a stroke. Score from 0 (best) to 42 (worst)
Change from baseline Stroke Impact Scale (SIS) score at 6 months
Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale
Time Frame: Change from baseline Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale score at 6 months
Self-reported measure of upper-extremity efficacy in activities of daily living. Score from 0 (worst) to 10 (best).
Change from baseline Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale score at 6 months
Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Self-management subscale
Time Frame: Change from baseline Self-Efficacy Questionnaire (SSEQ) - Self-management subscale score at 6 months
Self-reported measure of upper-extremity efficacy in activities of daily living. Score from 0 (worst) to 10 (best).
Change from baseline Self-Efficacy Questionnaire (SSEQ) - Self-management subscale score at 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of times the activity goals are reached
Time Frame: At 6 months
Number of times the activity goals set are reached over the study duration
At 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paolo Bonato, PhD, Spaulding Rehabilitation Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 8, 2025

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

August 31, 2026

Study Registration Dates

First Submitted

January 21, 2025

First Submitted That Met QC Criteria

January 27, 2025

First Posted (Actual)

January 28, 2025

Study Record Updates

Last Update Posted (Actual)

November 28, 2025

Last Update Submitted That Met QC Criteria

November 21, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Usual Care + Sham

Subscribe